Alclomethasone (Alclomethasonum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Dermatotropona funds

Glucocorticosteroids

Included in the formulation
  • Afloderm®
    ointment externally 
    Beluga, medicines and cosmetics.     Croatia
  • Afloderm®
    cream externally 
    Beluga, medicines and cosmetics.     Croatia
    • АТХ:

    D.07.A.B   Corticosteroids are moderately active (group II)

    D.07.A.B.10   Alclomethasone

    Pharmacodynamics:

    Glucocorticoids penetrate into the cell and interact with intracellular glucocorticoid receptors. Formation of dimers of the glucocorticoid complex-glucocorticoid receptor" and release of the receptor from bonds with heat shock proteins 70 and 90, as well as immunophilin, lead to the transfer of activated receptors into the nucleus, binding to glucocorticoid-sensitive regulatory elements of DNA, causing a specific effect on gene expression (activation and inhibition). Interaction with other protein transcription factors, including NFkB and AP-1, which regulate the expression of many proteins of the immune system, leads to suppression of the expression of genes that encode immunotropic and pro-inflammatory cytokines, collagenase and stromelysins. In addition, glucocorticoids by increasing the synthesis of lipocortins inhibit foslipazu A2, which leads to anti-inflammatory effect.

    Pharmacokinetics:

    Absorption from the surface of the skin. The connection with plasma proteins is high.Biotransformation in the liver (after entering the systemic circulation) to inactive metabolites (CYP3A4). Half-life - 1,3-1,7 hours Elimination mainly kidney in the form of inactive metabolites.

    Indications:

    Atopic dermatitis, diffuse neurodermatitis, simple and allergic dermatitis; discoid lupus erythematosus; eczema; red flat lichen; multiforme exudative erythema; itching of the skin, psoriasis, seborrheic dermatitis, xerosis; in children: inflammatory skin diseases, such as eczema.

    ICD-10

    XII.L20-L30.L20.8   Other atopic dermatitis

    XII.L20-L30.L21   Seborrheic dermatitis

    XII.L20-L30.L23   Allergic contact dermatitis

    XII.L20-L30.L24   Simple irritant contact dermatitis

    XII.L20-L30.L28.0   Simple chronic lichen

    XII.L20-L30.L29   Itching

    XII.L20-L30.L29.3   Anogenital itching, unspecified

    XII.L20-L30.L30.0   Coin-like eczema

    XII.L55-L59.L56.2   Photocontact dermatitis [berloque dermatitis]

    Contraindications:

    Individual intolerance; syphilis; lupus; diaper rash; rosacea; extensive psoriatic plaques; anogenital itching; skin infections caused by bacteria, viruses, fungi: pyoderma, chicken pox, herpes, actinomycosis, blastomycosis, sporotrichosis; trophic ulcers of the lower leg,associated with varicose veins; erosive and ulcerative lesions of the gastrointestinal tract; wounds on application areas; skin cancer; nevus, atheroma, melanoma, hemangioma, xanthoma, sarcoma; pregnancy, breast-feeding; children's age (up to 6 months).

    Carefully:No data.
    Pregnancy and lactation:

    Use of the drug during pregnancy is possible for a short period of time and on small surfaces in the case where the expected effect of therapy exceeds the potential risk to the fetus.

    FDA Action Category - C.

    When breastfeeding, do not apply the drug to the skin of the breast before feeding.

    Dosing and Administration:

    Apply externally 2-3 times a day or more, depending on localization.

    Side effects:

    Skin: burning, itching, steroid acne, erythema steroid, striae, dry skin, folliculitis, tingling. With long-term use - skin atrophy, hypertrichosis, telangiectasia, purpura, skin pigmentation disorders, alopecia, especially in women.

    Secondary immunodeficiency (exacerbation of chronic infectious diseases, generalization of the infectious process, development of opportunistic infections).

    When applied to large surfaces - systemic manifestations (gastritis, "steroid" stomach ulcer, adrenal insufficiency, Itenko-Cushing syndrome, "steroid" diabetes, slowing of reparative processes, etc.).

    Overdose:

    In case of an overdose perhaps increased blood sugar, the appearance of sugar in the urine (hyperglycemia and glycosuria, respectively), oppression of the adrenal cortex function, Itenko-Cushing syndrome.

    For the treatment of overdose, it is necessary to cancel the drug and symptomatic therapy.

    Interaction:

    When using glucocorticoids for external use in recommended doses, the probability of their interaction with other agents is negligible.

    Special instructions:No data.
    Instructions
    Up